The Effectiveness of Antiplatelet Therapy in COVID-19 Patients: A Narrative Literature Review
DOI:
https://doi.org/10.37275/bsm.v7i1.751Keywords:
Antiplatelet drugs, COVID-19, Cytokine storm, Omicron type, PneumoniaAbstract
Coagulopathy is a feature of severe COVID-19 disease and contributes to an increased risk of thromboembolic complications and death. This literature review aimed to describe the effectiveness of antiplatelet therapy in COVID-19 patients. There is an inverse relationship between the likelihood of COVID-19 infection, duration of illness and death, and use of antiplatelets for primary prevention. A study showed that COVID-19 patients who did not receive antiplatelet drugs had three times the risk of dying with antiplatelet drugs. This study shows the strong effect of antiplatelet drugs on reducing the mortality rate of COVID-19 patients. Another study showed that COVID-19 patients who received antiplatelet drugs had 1.18 times the risk of dying than those without antiplatelet drugs. This study shows that antiplatelet therapy does not affect the reduction in mortality in patients hospitalized with COVID-19. In conclusion, the effectiveness of antiplatelet administration in COVID-19 patients is still unclear, so further research is needed.
Authors
- Muhammad Ridhwan Fatharanifurqan1*
- Rudy Afriant2
- Raveinal3
- Fauzar4
- Drajad Priyono5
- 1Department of Internal Medicine, Faculty of Medicine, Universitas Andalas/Dr. M. Djamil General Hospital, Padang, Indonesia
- 2Division of Hematology and Oncology, Department of Internal Medicine, Faculty of Medicine, Universitas Andalas/Dr. M. Djamil General Hospital, Padang, Indonesia
- 3Division of Allergy and Immunology, Department of Internal Medicine, Faculty of Medicine, Universitas Andalas/Dr. M. Djamil General Hospital, Padang, Indonesia
- 4Division of Pulmonology, Department of Internal Medicine, Faculty of Medicine, Universitas Andalas/Dr. M. Djamil General Hospital, Padang, Indonesia
- 5Division of Nephrology and Hypertension, Department of Internal Medicine, Faculty of Medicine, Universitas Andalas/Dr. M. Djamil General Hospital, Padang, Indonesia
Corresponding author Muhammad Ridhwan Fatharanifurqan — Ridh_wan14@yahoo.co.id
Article history
- Submitted
- Accepted
- Published
Downloads
Published
Issue
Section
License
As our aim is to disseminate original research article, hence the publishing right is a necessary one. The publishing right is needed in order to reach the agreement between the author and publisher. As the journal is fully open access, the authors will sign an exclusive license agreement.
The authors have the right to:
- Share their article in the same ways permitted to third parties under the relevant user license.
- Retain copyright, patent, trademark and other intellectual property rights including research data.
- Proper attribution and credit for the published work.
For the open access article, the publisher is granted to the following right.
- The non-exclusive right to publish the article and grant right to others.
- For the published article, the publisher applied for the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
